Articles

KIT D816V mutations are highly associated with most cases of systemic mastocytosis. Avapritinib demonstrates efficacy in controlling disease progression in patients with KIT D816V mutations.

Advanced systemic mastocytosis often develops in patients aged >60 years but some younger patients qualify for Medicare due to preexisting disability. All patients with advanced systemic mastocytosis require more healthcare resources and have greater medical costs.

Clinical trials in systemic mastocytosis have led to the development of new prognostic scoring systems. Although effective in a controlled study, their usefulness in identifying high-risk patients in a real-world clinical setting requires further evaluation.

Bezuclastinib treatment has shown clinical activity in advanced solid tumors with little toxicity. A phase 2 investigation seeks to determine its potential as a safe and effective option for KIT D816V–driven advanced systemic mastocytosis.